Mazdutide 10 mg – 10 Vials

Mazdutide (also known as IBI362 or LY3305677) is a synthetic peptide research compound and mammalian oxyntomodulin analog designed as a once-weekly dual agonist of the glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR). It mimics the actions of endogenous oxyntomodulin, with balanced activation of GLP-1R to promote glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite, while GCGR agonism enhances energy expenditure, hepatic fatty acid oxidation, lipid metabolism, and counteracts potential hyperglycemia from glucagon effects. In preclinical and clinical models (including phase 2/3 trials such as DREAMS and GLORY series), mazdutide achieves substantial body weight reductions (often 15-20% or more over 24-68 weeks at higher doses), superior glycemic control (e.g., significant HbA1c lowering), improved cardiometabolic parameters (e.g., reduced blood pressure, lipids, liver fat, inflammation, and serum uric acid), and additional benefits like potential neuroprotection in metabolic disorder models. The dual agonism provides synergistic effects beyond GLP-1 mono-agonists (e.g., semaglutide), overcoming compensatory mechanisms in energy balance for enhanced weight loss and metabolic homeostasis. Mazdutide is utilized in research to investigate multi-receptor incretin/glucagon pathways, therapeutic strategies for obesity, type 2 diabetes, metabolic syndrome, non-alcoholic fatty liver disease, hyperuricemia, and emerging roles in cognitive function preservation in diabetes-associated conditions, as well as comparative efficacy with other incretin-based therapies in long-term weight management and metabolic reprogramming.